<?xml version="1.0" encoding="UTF-8"?>
<p>PON1 enzyme levels can range widely even between individuals with the same PON1 genotypes, and hence PON1 status which considers both PON1 genotypes and PON1 activity is a more informative for use in epidemiological studies then PON1 genotype alone
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>. Due to the relatively high concentrations of PON1 in human blood, many studies have also been performed on the inhibitory effect of medical drugs
 <xref rid="CIT0013" ref-type="bibr">
  <sup>13–16</sup>
 </xref> or metal elements
 <xref rid="CIT0017" ref-type="bibr">
  <sup>17</sup>
 </xref> on PON1 activity. Recent studies have shown that there is also a specific interaction of MPO-apoAI-PON1 on HDL surface that seems to be germane to the development of different diseases
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>. Therefore, PON1 studies widely utilise various assays for determination of PON1 phenotypes whenever possible, but unfortunately they are usually limited only on the specific enzyme activity measurements, and mostly with highly toxic substrates
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3–6</sup>
 </xref>.
</p>
